152 / 1084
USA – CALGB 80803
Key results (cont.)
pCR rates
Induction
mFOLFOX
(n=129)
PET responder
73/129 (57%)
PET non-responder
39/129 (30%)
Induction
carboplatin/paclitaxel
(n=128)
PET responder
64/128 (50%)
PET non-responder
49/128 (38%)
36
© Universitätsmedizin Leipzig: University Cancer Center Leipzig (UCCL), Prof. Dr. F. Lordick
Goodman KA, et al. J Clin Oncol 2017; 35 (suppl 4): abstr 1
*One ypTON1 excluded
Concurrent mFOLFOX
pCR: 24/64 (37.5%)
Concurrent
carboplatin/paclitaxel
pCR: 7/37 (19.0%)
Concurrent
carboplatin/paclitaxel
pCR: 7/56 (12.5%)
Concurrent mFOLFOX
pCR: 7/41* (17.0%)